My NCBISign In

Display Settings:

Format

Send to:

Choose Destination

    Neurology. 2001 Oct 9;57(7):1313-6.

    Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy.

    Schifitto G, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra CM, Rubin M, Cohen BA, Tucker T, Koralnik IJ, Katzenstein D, Haidich B, Smith ME, Shriver S, Millar L, Clifford DB, McArthur JC; AIDS Clinical Trials Group Team 291.

    Department of Neurology, University of Rochester, NY 14642, USA. gschifitto@mct.rochester.edu

    Abstract

    HIV-associated distal sensory polyneuropathy (DSP) is a common complication of AIDS. No effective treatment is available. The authors investigated the long-term effect (48 weeks) of the neurotrophin nerve growth factor (NGF) in an open-label study of 200 subjects with HIV-associated DSP. Similar to their previously reported double-blind study, the authors showed that NGF was safe and well tolerated and significantly improved pain symptoms. However, there was no improvement of neuropathy severity as assessed by neurologic examination, quantitative sensory testing, and epidermal nerve fiber density.

    PMID: 11591856 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...
    Write to the Help Desk